🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Health Concern

The sexually transmitted infection are escalating worldwide, with estimates suggesting more than 82 million new cases annually. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs currently available.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

One new antibiotic, marketed under the name a brand name, was authorized by the American regulatory agency in December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts believe that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, gained clearance in concurrent days. This drug, which is also used to treat UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This approval marks a significant shift in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

As per findings detailed in a major medical journal, zoliflodacin eradicated the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which combines two antibiotics. The research involved nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to make available and distribute the drug in numerous developing nations.

Clinicians on the front lines have shared hope. Having a single-dose, oral treatment of this kind is described as a "revolutionary step" for gonorrhoea control. This is deemed vital to lessen the impact of the illness for people and to prevent the spread of untreatable gonorrhoea globally.